Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update
April 29, 2021 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Presentation of Two Abstracts at ASCO 2021 Virtual Meeting
April 28, 2021 10:00 ET
|
Oncternal Therapeutics
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Appointment of Chase Leavitt as General Counsel
April 12, 2021 16:41 ET
|
Oncternal Therapeutics
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces Presentation of Three Posters at AACR 2021 Virtual Meeting
April 12, 2021 07:00 ET
|
Oncternal Therapeutics
Updated interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer showed 57% of evaluable patients (8 of 14) had a...
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2021 16:38 ET
|
Oncternal Therapeutics
SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2020 Financial Results
March 11, 2021 16:01 ET
|
Oncternal Therapeutics
Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December 2020 compare favorably to historical single-agent ibrutinib data (47% CR vs. 20% CR historical single-agent...
Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update
March 04, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in March Investor Conferences
February 24, 2021 08:00 ET
|
Oncternal Therapeutics
- H.C. Wainwright: Global Life Sciences Conference - March 9th – 10th - Oppenheimer 31st Annual Healthcare Conference - March 16th – 17th SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Oncternal...
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
February 22, 2021 17:33 ET
|
Oncternal Therapeutics
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
January 28, 2021 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...